New report shows 2% decrease in anxiolytic and hypnotic sales in Norway

NewsGuard 100/100 Score

After many years of gradual increase followed by a three-year levelling off period, sales of addictive anxiolytic and hypnotic drugs decreased by just under two per cent in 2010.

This comes from the new report "Drug Consumption in Norway 2006-2010". The statistics include all sales of prescription and OTC drugs in Norway from wholesalers to pharmacies, hospitals / nursing homes and grocery stores. The report also shows that total sales of OTC medicines measured in DDDs declined by six per cent in 2010.

This is mainly due to lower sales of OTC packets of paracetamol and ibuprofen. If prescription packs of paracetamol and ibuprofen are included, the sale of these two drugs was relatively stable in 2010. This means that more people are being prescribed these medicines by their doctor.

In 2010, wholesalers sold drugs for 12.3 billion Norwegian kroner in Norway, of which veterinary drugs accounted for 500 million kroner. Calculated by sales price, this gives a turnover of just under 19 billion kroner in 2010, a decline of 1.1 per cent compared to 2009. The decrease is mainly due to sales in 2009 being affected by the influenza pandemic (sales of Pandemrix- vaccine and other influenza medicines, especially Tamiflu-). In addition, the introduction of price regulatory measures and preferred drugs within certain groups, such as for treatment of high blood pressure, resulted in reduced costs.

Sales of drugs measured in doses (DDD) increased by 0.9 per cent in 2010. There have only been minor changes in most drug groups.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Newly identified antibodies target a hard-to-spot region of the influenza virus